We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

BVXP Bioventix Plc

-70.00 (-1.50%)
12 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Bioventix Plc LSE:BVXP London Ordinary Share GB00B4QVDF07 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -70.00 -1.50% 4,600.00 4,500.00 4,700.00 4,675.00 4,600.00 4,675.00 4,706 13:23:21
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Coml Physical, Biologcl Resh 12.82M 8.37M 1.6071 28.62 239.63M
Bioventix Plc is listed in the Coml Physical, Biologcl Resh sector of the London Stock Exchange with ticker BVXP. The last closing price for Bioventix was 4,670p. Over the last year, Bioventix shares have traded in a share price range of 3,450.00p to 5,060.00p.

Bioventix currently has 5,209,333 shares in issue. The market capitalisation of Bioventix is £239.63 million. Bioventix has a price to earnings ratio (PE ratio) of 28.62.

Bioventix Share Discussion Threads

Showing 1451 to 1475 of 1575 messages
Chat Pages: 63  62  61  60  59  58  57  56  55  54  53  52  Older
"we are pleased to see a solid performance of our core business and look forward to this continuing over the remainder of the year"
That's pretty bullish for the traditionally VERY conservative BVXP.
On the Alzheimers test "the outlook remains exciting" is also pretty bullish.
I'm happy to remain invested and may well add on any dips. This company has never let us investors down. They signal when things won't be super and usually outperform. And the Board are bargain prices. I was pleased to see them take some reward off the table recently selling some shares.

Is that Turnover growth likely to continue for rest of the year? Growth had been a lot lower over the last 5 years - more like 10-15%. Is this down to Troponin?

If we get the same growth to the end of the year that would be turnover around 14.5m, Operating profit almost 10m, and EPS roughly 180p, for a P/E of 22. (Lots of assumptions in that figure, but my forecasts have always turned out to be low in previous years except for 2021).

However, the share price is largely unchanged over the last 4 years. Don't know what it would take to change that, the company is just too small for many.

What do people think is going to happen in the medium/long term here. Will the company get sold at some point? When will Peter Harrison retire? I know nobody knows the answers, but happy for some idle speculation in the meantime :-)

also added a few... nice increase in dividend and very positive results. whats not to like?
Yep - continuing to build a position - added a few more this am.

I used to go fishing - and when the river was high, I fished in different places out of the main stream.... those pools used to hold some good fish. And I use the analogy because BVXP is out of the mainstream and unaffected by current macro events. A good place to be fishing IMV but DYOR!

Indeed, such a super well-run company. Congrats if they're reading.
Nice half year results and a 20% dividend hike.
Looks like some excitement in Gothenberg too.
Happy to hold.

Thanks for the additional info, I realise there are still market makers involved with some stocks, but I still think these should be thought of as trades, and that the buy/sell labels assigned by websites should be ignored as meaningless.
and the market maker will have received stock from someone who sold in a separate transaction of which we know nothing. In my experience the quoted spread is often misleadingly wide and purchases are often done well within the implied mid price.
alter ego
Except that with SETSqx stocks the counterparty isn't a someone its a market maker. For whatever reason the trade price was below the mid point of bid and ask and the market makers give the impression that melody9999's trade was a sell from him to the market maker when he knows he bought some. Hope that helps.
melton john
There's only one transaction - it's a trade, with both a buyer and a seller.
then that would have appeared as a different transaction - can you identify the price of that sale?
alter ego
It was a sell - someone sold them to you !!
Just added a few more at 3884p Shown as a sell.
I said he'd sold £2m!!!
I'm not going to criticise the CEO though, the best run company on AiM by a country mile and he thoroughly deserves his £££.

I suspect the drop is not on the options but on the CEO selling about 14% of his holding raising over £2m. Not only that, but doing so immediatelely before the close period is a red flag in some books.
Bit of a drop as Directors (mostly CEO) exercise options and cash in £2m of shares at £37.50
Thanks Maynard - added to the header.


An interesting listen - thanks for posting TMFMayn.
Looks like £40 is a reasonable current value.

[Podcast] BIOVENTIX With Roland Head And Maynard Paton #BVXP

A podcast about antibody specialist BIOVENTIX with shareholders Roland Head and Maynard Paton. We talked about the wonderful longevity of diagnostic antibodies, the group's super financials, the potential for Alzheimer's testing and management's remarks at the AGM:

Show notes here:

".........the FDA said that the phase 3 results seemed to support its decision to grant accelerated approval, which allows drugs onto the market before efficacy has been proved."

The fact that they are granting approval before proof of efficacy is very interesting in itself. Much was made of accelerated covid approvals along the same lines. In the latter case it was very much a desperation measure. Not so alzeimers.

The next point is cost/affordability. (£21 840; €24 640) per patient per year is expensive at face value. That has to be set against the number of suitable patients requiring treatment.
What is the onging cost for the current treatments offered to patients with alzeimers, related to the increased life expectancy of those patients?
Those are hard facts, set against the emotional needs of the patients and their families.

Once the numbers are established, both the health services and the company can assess the outcomes for both sides of the equation.
It may be hard nosed to set them side by side, but then life is tough and it doesn't last forever. In a world where there is insufficient funding for health services to fund all treatments available to them, it is something of a routine daily task - determining which patients have priority.


BMJ today.

"The US Food and Drug Administration (FDA) has approved lecanemab (Leqembi) for treatment of Alzheimer’s disease despite questions over whether the drug will make a difference to patients.

The agency approved the drug through its accelerated approval pathway, stating that the decision was based on phase 2 trial data that showed a reduction in amyloid β (Aβ) plaques in patients at an early stage. As such, the FDA has said that lecanemab should be initiated only in patients with mild cognitive impairment or in those in the mild dementia stage of disease.

Lecanemab, which is priced at $26 500 (£21 840; €24 640) per patient per year, binds to and eliminates Aβ aggregates that are thought to contribute to neurodegenerative processes in Alzheimer’s disease. While the phase 2 trial of 856 patients did not meet its 12 month primary endpoint (clinical change on the Alzheimer’s Disease Composite Score), researchers reported a “reduction in brain amyloid accompanied by a consistent reduction of clinical decline across several clinical and biomarker endpoints” at 18 months.1

Additionally, the phase 3 results, published in the New England Journal of Medicine in December, showed that lecanemab administered by intravenous infusion every two weeks reduced markers of amyloid and resulted in “moderately less” decline on measures of cognition and function after 18 months when compared with placebo.2

Although not officially reviewed by decision makers, the FDA said that the phase 3 results seemed to support its decision to grant accelerated approval, which allows drugs onto the market before efficacy has been proved."

Dementia treatment will grab headlines but may not deliver income in a hurry.


Lecanemab won accelerated approval from the US Food and Drug Administration on Friday last week
FYI - understanding Alzheimer's

This Neurologist Shows You How You Can Avoid Cognitive Decline | Dr. Dale Bredesen on Health Theory

Have they any link with Biogen ?
Not sure I saw this posted from early-December - Keith Ashworth-Lord in the IC:

"Keith Ashworth-Lord, chief investment officer of Sanford DeLand Asset Management and manager of CFP SDL UK Buffettology Fund (GB00BF0LDZ31), explains why he invests in antibody producer Bioventix (BVXP).

"Bioventix is one of the most attractive businesses in the Buffettology portfolio. It occupies a genuine niche where the economic moat [competitive advantages] is protected by regulatory affairs, in particular the need for product approval from regulators on both sides of the Atlantic, which can take several years to obtain.

"The product concerned is high affinity, monoclonal antibodies harvested from sheep. When you go to a GP for a blood test, your sample containing antigens gets mixed with a reagent containing antibodies. This is then read by a machine to determine if you have any conditions, such as vitamin D deficiency. Bioventix sells its product to the big five machine manufacturers and in return gets a royalty – typically 2 per cent – every time a test is done on its machine. For the manufacturer, the royalty is a relatively small proportion of cost and as long as the antibody is working, why take the risk of moving to an unproven rival product?

Growth has been consistent over the past 12 years with a compound annual growth rate in revenue of 10.1 per cent over the past five years and 17.3 per cent over the past 10 years. The slowdown is because its revenues from a major antibody terminated after 10 years, as planned, in August 2021 with the loss of £1.2mn in sales. In its last financial year, gross margin was 93.9 per cent and operating margin was 79.1 per cent – this is a product with very little cost of sales attached.

"The wealth of the business rests with its employees' expertise, of which there are just 17 in total. Per capita sales and profit are an astonishing £690,000 and £545,000, respectively. Being an asset-light business, the return on average equity is 63.8 per cent and the conversion of profit after tax to free cash flow has averaged at 101 per cent over the past five years. With its major costs being research and development, and staff, Bioventix is able to pay generous dividends. Including supplementary dividends, all and more of earnings per share (EPS) have been returned to shareholders for five years without fail."

Chat Pages: 63  62  61  60  59  58  57  56  55  54  53  52  Older

Your Recent History

Delayed Upgrade Clock